<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083406</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_13_007</org_study_id>
    <nct_id>NCT02083406</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)</brief_title>
  <official_title>Open Label Study to Investigate the Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose study to investigate how different formulations of OZ439 co-administered with
      PQP tablest are processed by the body when taken without food
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OZ439 AUC(0-168h)</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>OZ439 Area under the plasma concentration (AUC) versus time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>OZ439 Maximum observed concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Piperaquine (PQ) AUC(0-168h)</measure>
    <time_frame>Up to 168h post-dose</time_frame>
    <description>PQ Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PQ Cmax</measure>
    <time_frame>Up to 168h post-dose</time_frame>
    <description>PQ Maximum observed concentration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Treatment A: OZ439 Prototype 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: OZ439 Prototype 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: OZ439 Prototype 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800mg OZ439 prototype formulation 1</intervention_name>
    <arm_group_label>Treatment A: OZ439 Prototype 1</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800mg OZ439 prototype formulation 2</intervention_name>
    <arm_group_label>Treatment B: OZ439 Prototype 2</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800mg OZ439 prototype formulation 3</intervention_name>
    <arm_group_label>Treatment C: OZ439 Prototype 3</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>960mg PQP</intervention_name>
    <arm_group_label>Treatment A: OZ439 Prototype 1</arm_group_label>
    <arm_group_label>Treatment B: OZ439 Prototype 2</arm_group_label>
    <arm_group_label>Treatment C: OZ439 Prototype 3</arm_group_label>
    <other_name>Piperqauine phosphate as powder in bottle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males, or healthy females of non-childbearing potential ie surgically
             sterilised or post-menopausal (amenorrhoea for at least 1 year and confirmed by a
             follicle stimulating hormone result of ≥25 IU/mL

          2. Age 18 to 55 years of age

          3. Body mass index of 18.0 to 30.0 kg/m2 inclusive. Total body weight &gt;50 kg at screening

          4. Willing and able to communicate and participate in the whole study

          5. Must provide written informed consent

          6. Must agree to use an adequate method of contraception

          7. Must have liver function tests and haemoglobin within the laboratory reference range
             at screening and Day -1

          8. Must have heart trace measurements within the defined healthy limits at screening, Day
             -1 and pre-dose

        Exclusion Criteria:

          1. Male subjects who have currently pregnant partners

          2. Evidence or history of clinically significant oncological, pulmonary, chronic
             respiratory, hepatic, cardiovascular, haematological, metabolic, neurological,
             immunological, nephrological, endocrine or psychiatric disease, or current infection

          3. Clinically relevant abnormalities in the heart trace including any degree of heart
             block, including asymptomatic bundle branch block

          4. Family history of sudden death or of congenital prolongation of the QTc interval or
             known congenital prolongation of the QTc interval or any clinical condition known to
             prolong the QTc interval

          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia

          6. Electrolyte disturbances, particularly hypokalemia, hypocalcaemia or hypomagnesaemia.

          7. Any condition that could possibly affect drug absorption, such as gastrectomy or
             diarrhoea

          8. History of post-antibiotic colitis

          9. History of any drug or alcohol abuse in the past 2 years prior to screening

         10. Subjects who have a breath carbon monoxide reading of greater than 10 ppm at screening
             will be excluded. Subjects who are tobacco users (including smokers and users of
             snuff, chewing tobacco and other nicotine or nicotine-containing products) must have
             stopped use within 90 days before screening.

         11. Receipt of an investigational drug or participation in another clinical research study
             within 90 days prior to drug administration.

         12. Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee.

         13. Subjects who have previously been enrolled in this study

         14. Use of ANY prescription or non-prescription medications, vitamins, herbal supplements
             or dietary supplements, including protein supplements, within 14 days prior to the
             first dose of study drug and throughout the study, unless prior approval is granted by
             both the investigator and the sponsor. An exception will be made for intermittent use
             of paracetamol and hormone replacement therapy. Paracetamol at doses of, at most, 2 g
             per day or no more than 3 consecutive days or 6 non consecutive days, are allowed
             until 24 hours before dosing with study drug. Longer exclusion periods apply for:

               1. amiodarone and hydroxychloroquine (210 days)

               2. monoclonal antibodies/ immunoglobulins/ other therapeutic proteins and
                  experimental drugs for which the half-life is not known to the investigator (120
                  days)

               3. experimental drugs for which half-life is known to the investigator (5 half lives
                  plus 14 days)

               4. chloroquine, piperaquine phosphate and flunarizine (100 days)

               5. fluoxetine (75 days)

               6. benzodiazepines (for midazolam, lorazepam and triazolam, the exclusion period is
                  14 days), chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone,
                  phenprocoumone and cytochrome P450 3A4 inducers not already mentioned, including
                  but not restricted to, rifampin, carbamazepine, oxcarbazepine, phenytoin and St
                  John's Wort (35 days)

         15. Positive hepatitis B surface antigen, hepatitis C virus antibody or human
             immunodeficiency virus results

         16. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by
             the investigator

         17. Positive urine drug screen result at screening or admission to the clinical unit

         18. History of intolerance or hypersensitivity to piperaquine or any 4-aminoquinolone, or
             ascertained or presumptive hypersensitivity to the active principle and/or formulation
             ingredients; history of anaphylaxis to drugs or allergic reactions in general, that
             the investigator considers may affect the outcome of the study

         19. Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

         20. Presence or history of allergy requiring treatment; hayfever is allowed unless it is
             active

         21. Donation or loss of &gt;400 mL of blood within 90 days prior to drug administration

         22. Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week
             (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

         23. Subjects who do not have suitable veins for multiple blood samples as assessed by the
             investigator at screening

         24. Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Collier, MBChB FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2015</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Bio-availability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment A: OZ439 Prototype 1</title>
          <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses under fasted conditions</description>
        </group>
        <group group_id="P2">
          <title>Treatment B: OZ439 Prototype 2</title>
          <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses under fasted conditions</description>
        </group>
        <group group_id="P3">
          <title>Treatment C: OZ439 Prototype 3</title>
          <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses under fasted conditions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment A: OZ439 Prototype 1</title>
          <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses under fasted conditions</description>
        </group>
        <group group_id="B2">
          <title>Treatment B: OZ439 Prototype 2</title>
          <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses under fasted conditions</description>
        </group>
        <group group_id="B3">
          <title>Treatment C: OZ439 Prototype 3</title>
          <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses under fasted conditions</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="8.2"/>
                    <measurement group_id="B2" value="44.9" spread="11.3"/>
                    <measurement group_id="B3" value="35.7" spread="4.1"/>
                    <measurement group_id="B4" value="36.6" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>OZ439 AUC(0-168h)</title>
        <description>OZ439 Area under the plasma concentration (AUC) versus time curve</description>
        <time_frame>Up to 168 hours post-dose</time_frame>
        <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for pharmacokinetics (PK) parameter estimation</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: OZ439 Prototype 1</title>
            <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: OZ439 Prototype 2</title>
            <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: OZ439 Prototype 3</title>
            <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC(0-168h)</title>
          <description>OZ439 Area under the plasma concentration (AUC) versus time curve</description>
          <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for pharmacokinetics (PK) parameter estimation</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8780" spread="43.7"/>
                    <measurement group_id="O2" value="10300" spread="23.7"/>
                    <measurement group_id="O3" value="9460" spread="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OZ439 Cmax</title>
        <description>OZ439 Maximum observed concentration</description>
        <time_frame>Up to 168 hours post-dose</time_frame>
        <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for PK parameter estimation</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: OZ439 Prototype 1</title>
            <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: OZ439 Prototype 2</title>
            <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: OZ439 Prototype 3</title>
            <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>OZ439 Maximum observed concentration</description>
          <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for PK parameter estimation</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="877" spread="41.3"/>
                    <measurement group_id="O2" value="995" spread="32.2"/>
                    <measurement group_id="O3" value="924" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Piperaquine (PQ) AUC(0-168h)</title>
        <description>PQ Area under the plasma concentration versus time curve</description>
        <time_frame>Up to 168h post-dose</time_frame>
        <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for PK parameter estimation</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: OZ439 Prototype 1</title>
            <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: OZ439 Prototype 2</title>
            <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: OZ439 Prototype 3</title>
            <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine (PQ) AUC(0-168h)</title>
          <description>PQ Area under the plasma concentration versus time curve</description>
          <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for PK parameter estimation</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3730" spread="41.3"/>
                    <measurement group_id="O2" value="2810" spread="21.8"/>
                    <measurement group_id="O3" value="3300" spread="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PQ Cmax</title>
        <description>PQ Maximum observed concentration</description>
        <time_frame>Up to 168h post-dose</time_frame>
        <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for PK parameter estimation</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: OZ439 Prototype 1</title>
            <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: OZ439 Prototype 2</title>
            <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses under fasted conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: OZ439 Prototype 3</title>
            <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses under fasted conditions</description>
          </group>
        </group_list>
        <measure>
          <title>PQ Cmax</title>
          <description>PQ Maximum observed concentration</description>
          <population>All subjects who received at least one dose of study drug and had sufficient plasma concentration data for PK parameter estimation</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" spread="90.1"/>
                    <measurement group_id="O2" value="89.5" spread="54.1"/>
                    <measurement group_id="O3" value="91.2" spread="130.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 43 post-dose</time_frame>
      <desc>All 22 subjects received one dose of OZ439 in combination with PQP and were included in the safety analysis population</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: OZ439 Prototype 1</title>
          <description>800mg OZ439 prototype formulation 1 and 960mg PQP single doses under fasted conditions</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: OZ439 Prototype 2</title>
          <description>800mg OZ439 prototype formulation 2 and 960mg PQP single doses under fasted conditions</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: OZ439 Prototype 3</title>
          <description>800mg OZ439 prototype formulation 3 and 960mg PQP single doses under fasted conditions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fiona Macintyre, PhD</name_or_title>
      <organization>Medicines for Malaria Venture (MMV)</organization>
      <phone>+41 22 555 0319</phone>
      <email>macintyref@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

